GlassScriptPhysician profile
Jaya Telang
NPI 1588357826
$1,269.81
in general payments reported to CMS, 2019-2025
16 companies · $508 in 2025
The $508 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $130 · 2024: $632 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,202 · Education: $68.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,201.81 |
| Education | $68.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $283.51 | 2024 | Illuccix |
| Mimedx Group, INC. | $172.91 | 2024 | |
| Calyxo, INC. | $156.16 | 2025 | Cvac Aspiration System |
| Ferring Pharmaceuticals INC. | $138.92 | 2025 | Adstiladrin |
| Olympus America INC. | $129.64 | 2023 | Soltive |
| Astellas Pharma US INC | $115.38 | 2024 | Xtandi |
| Janssen Biotech, INC. | $85.42 | 2025 | Erleada |
| Immunitybio, INC. | $31.88 | 2025 | |
| Celltrion USA INC. | $24.15 | 2025 | Vegzelma |
| Dendreon Pharmaceuticals LLC | $23.02 | 2024 | Provenge |
| Sumitomo Pharma America, INC. | $22.55 | 2025 | Orgovyx |
| Boston Scientific Corporation | $22.22 | 2024 | |
| Coloplast Corp | $22.22 | 2025 | |
| Urogen Pharma, INC. | $17.13 | 2025 | |
| Merck Sharp & Dohme LLC | $15.20 | 2024 | Lynparza |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valencia Technologies Corporation | $9.50 | 2025 | Ecoin Device Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaya Telang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.